Edition:
United States

Gilead Sciences Inc (GILD.MW)

GILD.MW on Midwest Stock Exchange

66.43USD
23 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$66.43
Open
$64.81
Day's High
$66.43
Day's Low
$64.81
Volume
500
Avg. Vol
18,183
52-wk High
$78.68
52-wk Low
$60.51

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  GILD.MW Industry Sector
P/E (TTM): 8.92 69.41 32.67
EPS (TTM): 9.21 -- --
ROI: 27.00 8.94 14.49
ROE: 63.92 10.07 15.79

Swiss stocks - Factors to watch on July 22

ZURICH/BERLIN, July 22 Here are some of the main factors that may affect Swiss stocks on Monday:

Jul 22 2019

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS

Jul 19 2019

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

Jul 16 2019

CORRECTED-UPDATE 2-GSK's two-drug HIV Dovato treatment meets main goal in study (July 10)

July 10 GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.

Jul 16 2019

CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

July 10 GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

Jul 16 2019

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

Jul 15 2019

US STOCKS-S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high

* Boeing drops on report 737 MAX groundings could extend to 2020

Jul 15 2019

UPDATE 4-Gilead invests $5 bln to deepen ties with biotech Galapagos

* Gilead makes $3.95 bln upfront payment, $1.1 equity investment

Jul 15 2019

US STOCKS-S&P trades near flat as Citigroup results weigh on bank stocks

* Dow flat, S&P flat, Nasdaq up 0.18% (Updates to late afternoon New York trade, changes byline, adds NEW YORK to dateline)

Jul 15 2019

US STOCKS-Wall Street slightly lower as Citi results weigh on bank stocks

* Indexes down: Dow 0.12%, S&P 0.15%, Nasdaq 0.07% (Updates to early afternoon)

Jul 15 2019

Earnings vs. Estimates